Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
11.95
-0.03 (-0.25%)
At close: Dec 5, 2025, 4:00 PM EST
11.93
-0.02 (-0.17%)
After-hours: Dec 5, 2025, 7:37 PM EST
Kura Oncology Stock Forecast
Stock Price Forecast
The 9 analysts that cover Kura Oncology stock have a consensus rating of "Buy" and an average price target of $25, which forecasts a 109.21% increase in the stock price over the next year. The lowest target is $10 and the highest is $40.
Price Target: $25 (+109.21%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Kura Oncology stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 2 |
| Buy | 5 | 5 | 6 | 6 | 6 | 7 |
| Hold | 2 | 2 | 2 | 3 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 13 | 14 | 13 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $11 → $28 | Buy | Maintains | $11 → $28 | +134.31% | Nov 24, 2025 |
| UBS | UBS | Strong Buy Maintains $14 → $16 | Strong Buy | Maintains | $14 → $16 | +33.89% | Nov 14, 2025 |
| Wedbush | Wedbush | Buy Maintains $36 → $38 | Buy | Maintains | $36 → $38 | +217.99% | Nov 14, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $24 | Buy | Reiterates | $24 | +100.84% | Oct 20, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +234.73% | Oct 20, 2025 |
Financial Forecast
Revenue This Year
128.33M
from 53.88M
Increased by 138.16%
Revenue Next Year
214.78M
from 128.33M
Increased by 67.37%
EPS This Year
-2.67
from -2.02
EPS Next Year
-2.50
from -2.67
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 238.5M | 473.8M | ||||
| Avg | 128.3M | 214.8M | ||||
| Low | 26.5M | 60.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 342.6% | 269.2% | ||||
| Avg | 138.2% | 67.4% | ||||
| Low | -50.9% | -52.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.58 | -0.60 | ||||
| Avg | -2.67 | -2.50 | ||||
| Low | -3.61 | -3.74 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.